Amerigen’s growth business development strategy is focused on three key principles: internal product development; collaborative development; and in-licensing/acquisitions of products and technologies.

愛(ài)美津制藥全球業(yè)務(wù)發(fā)展戰(zhàn)略包含三個(gè)方面：內(nèi)部產(chǎn)品開(kāi)發(fā)、合作開(kāi)發(fā)、以及產(chǎn)品與技術(shù)和許可和并購(gòu)。

In the US market, Amerigen is committed in developing generic and complex products with a robust pipeline of more than 30 ANDAs, half of them are high value First-to-File (FTF) opportunities. In the China market, excepting for commercializing Amerigen’s existing portfolio of approved products, Amerigen is bringing selected complex US ANDAs to China, following the recent regulations by CFDA.

在美國(guó)市場(chǎng)，愛(ài)美津致力于高難度仿制藥的開(kāi)發(fā)，目前已經(jīng)擁有了30多個(gè)產(chǎn)品的產(chǎn)品線，其中近一半是高附加值的首報(bào)產(chǎn)品（First-to-file Product）。在中國(guó)市場(chǎng)，除了銷售與合作目前已經(jīng)獲批的產(chǎn)品之外，愛(ài)美津順應(yīng)目前中國(guó)政府的改革，目前正選擇性的將美國(guó)的高難度仿制藥產(chǎn)品引入到中國(guó)市場(chǎng)。

As we expand our China pharmaceuticals business, Amerigen is committed to seeking local partnerships that fit our capabilities, enhance our corporate goals and strengthen our competitive position. We regard partnership and collaboration as an integral part of our China business development strategy. This important initiative is supported by a local BD team.

目前我們正在積極開(kāi)拓中國(guó)市場(chǎng)的業(yè)務(wù)，愛(ài)美津希望尋求本土的合作機(jī)會(huì)，能夠符合公司的戰(zhàn)略目標(biāo)、適合公司的核心競(jìng)爭(zhēng)力并能夠提升公司的競(jìng)爭(zhēng)地位。這類合作是中國(guó)業(yè)務(wù)拓展戰(zhàn)略非常重要的一部分，目前由本土的業(yè)務(wù)拓展團(tuán)隊(duì)負(fù)責(zé)。

Besides US and China market, Amerigen will also evaluate opportunities in other territories if they may provide strategic returns for the company.

除了美國(guó)和中國(guó)市場(chǎng)，愛(ài)美津也會(huì)評(píng)估其它國(guó)家/地域的機(jī)會(huì)，如果這些機(jī)會(huì)能夠給公司帶來(lái)戰(zhàn)略上的回報(bào)。

 

If your firm is interested in working with Suzhou Amerigen, contact us.